We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the ...

Genmab (GMAB) stock was downgraded by Bernstein due to a looming patent cliff for Darzalex, a blood cancer drug marketed by the company with J&J (JNJ). Read more here.

Bernstein downgraded Genmab (GMAB) to Underperform from Market Perform with a price target of DKK 1,000, down from DKK 1,580. The share price ...

Bernstein analyst Justin Smith downgraded Genmab A/S (0MGB – Research Report) to a Sell on March 28 and set a price target of DKK1,000.00. The ...

AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s ...

Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

The complaint filed in a Seattle court alleges that Genmab, its subsidiary ProfoundBio – which was acquired last year – and ...

Investing.com -- Bernstein analysts have downgraded Genmab A/S (CSE: GMAB) to an "underperform" rating from "market perform,” in a note dated Tuesday. Shares of the Danish biotechnology company were ...

We came across a bullish thesis on Genmab A/S (GMAB) on Substack by Oliver | MMMT Wealth. In this article, we will summarize ...

Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat ...